RE: 2nd of Oct Questions & Answeres31 Oct 2023 09:35
BV, I think the most cursory look at the SP's trajectory over the last several years makes it beyond clear that my own more wary view on ANGS has been pretty much spot on accurate. However, although you would look a deal less idiotic if you stopped making things up, you carry on averaging down as much as you like.
To provide some clarity on the new authorities to issue shares that ANGS just got given (unsurprisingly) as a result of yesterday's EGM, these fall into three lots:-
Lot 1. 516 million new shares which WILL be issued to Kemexon as payment for the first £3 million short-term/junior loan. For info, that £3m loan over six months cost the company (or rather, shareholders, in terms of imminent dilution) an additional £406k in interest and fees. Annualised, that's a fraction under 24%, so hardly cheap borrowing.
Lot 2a). 300 million new shares which WILL be issued to Aleph as warrants related to providing the second £6 million short-term/junior loan. This loan is under the same terms as the £3m one above and having ben extended once, becomes due for repayment in January.
Lot 2b). 1.5 billion new shares which MAY be issued in January to pay off the second £6 million short-term/junior loan, plus interest and fees. Rather than issuing these new shares at that time, ANGS could pay off that loan in cash (if it has enough at the time) or alternatively, if the replacement global refinancing package has been agreed at that time, then this could be used to pay off that loan instead of issuing new shares.
Lot 3. 2.762 billion new shares, which the company MAY issue in the future for whatever it sees fit.
That's a total new authority to issue up to 5.078 billion new shares, of which 816 million will definitely be issued very shortly (516 million actual new shares plus 300 million as warrants), of which 1.5 billion are fairly likely to be issued in January unless some other means of repayment is forthcoming, and of which 2.762 billion are additionally available to be issued, should the need arise.